Eupraxia Pharmaceuticals Inc. (EPRX)
| Previous Close | 2.5500 |
| Open | 2.4600 |
| Bid | 2.2600 x 100 |
| Ask | 2.8200 x 100 |
| Day's Range | 2.4500 - 2.5500 |
| 52 Week Range | 2.2000 - 3.5000 |
| Volume | |
| Avg. Volume | 7,746 |
| Market Cap | 90.367M |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings Date | Aug 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupLancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that Lancet Rheumatology, a leading independent, peer-reviewed journal committed to sharing progressive content relevant to rheumatology specialists worldwide, recently published Eupraxia's Phase 2 data from its SPRINGBOARD trial eval
PR NewswireEupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the upcoming United European Gastroenterology ("UEG") Week 2024 to be held in Vienna, Austria, on October 12-15, 2024.
PR NewswireEupraxia Pharmaceuticals Strengthens Senior Management Team
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the recent appointments of Chief Scientific Officer Amanda Malone, as Chief Operating and Scientific Officer, and Rahul Sarugaser, as Executive Vice President of Corporate Development.
